AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowships
The AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowship Program is designed to encourage exceptional clinical research by bridging close collaboration between academia and industry. Fellows have the opportunity to gain experience in early-stage and/or late-stage clinical development at the facilities of AstraZeneca in Gaithersburg, Maryland.
Dr. Chen earned his MD at Albert Einstein College of Medicine and completed internal medicine residency training at Stanford University. Currently, Dr. Chen is a hematology/oncology fellow at the University of California, Davis, and is enrolled in the Mentored Clinical Research Training Program, which grants a MAS degree in clinical research upon completion. His academic interests include immuno-oncology, early phase therapeutics, and applications of next-generation sequencing.
Acknowledgment of Support
I am thrilled and grateful to have been selected for the AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowship. This award offers me the opportunity to explore clinical trial design and execution from a unique perspective, complementing my prior research experience and further developing my career in investigational immuno-oncology.
Dr. Tschernia completed medical school at the University of Nevada School of Medicine, during which time he participated in the National Institutes of Health – Medical Research Scholars Program (MRSP). The MRSP afforded him the opportunity to be involved in the development of novel Chimeric Antigen Receptor (CAR) T-cell therapies targeting pediatric sarcomas and in the first intent-to-treat Phase 1 study of CARs targeting CD19 in pediatric B-cell ALL. He completed his internal medicine residency at the University of Rochester. He is currently a second-year hematology/oncology fellow at the University of North Carolina at Chapel Hill. He has a clinical interest in bone marrow transplant and is intent on developing a career centered on bridging the divide between novel cellular therapies in pre-clinical development and the patients who need them.
Acknowledgment of Support
The 2020 AACR-AstraZeneca Clinical Immuno-oncology Research Training Fellowship represents the ideal synergy between academia and industry, fostering the energy and dedication emboldened within early physician-scientists, and provides the ideal avenue of dedicated training to ensure our success. I am both humbled and overwhelmed with gratitude at this unique career-defining opportunity.